体内 CAR 基因治疗的前景与潜在陷阱
Promises and potential pitfalls of in vivo CAR gene therapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
T 细胞受体基因治疗在临床上靶向 TP53 公共新抗原
英文原题：T-cell Receptor Gene Therapy Clinically Targeting a TP53 Public Neoantigen.
查看英文原题
T-cell Receptor Gene Therapy Clinically Targeting a TP53 Public Neoantigen.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
T细胞受体（TCR）是一类抗原受体，能够独特地响应由胞质和核内蛋白产生的表位。在本期杂志中，Kim及其同事报告了首次成功应用TCR基因疗法靶向由TP53热点突变产生的共享或公共新抗原。这些结果确立了临床概念验证，即靶向致癌分子驱动因素中反复突变的现成TCR可以使转移性癌症患者获益。参见Kim等人的相关文章，第932页（4）。
展开英文摘要原文
T-cell receptors (TCR) are an antigen receptor class that can uniquely respond to epitopes resulting from cytosolic and intranuclear proteins. In this issue, Kim and colleagues report the first successful application of TCR gene therapy targeting a shared, or public, neoantigen resulting from a TP53 hotspot mutation. These results establish clinical proof of concept that an off-the-shelf TCR targeting a recurrent mutation in a molecular driver of oncogenesis can benefit patients with metastatic cancer. See related article by Kim et al., p. 932 (4) .
论文信息
- 作者
- Klebanoff CA
- 文献类型
- 社论 · 评论
- 期刊
- Cancer immunology research2022 Aug 3
- 原文标识
- PubMed 35767244 · DOI 10.1158/2326-6066.CIR-22-0386